FDA Commissioner Marty Makary Resigns Following Dispute Over Flavour Approval
Makary stepped down after the administration overrode his objections to authorising fruit-flavoured e-cigarettes, citing youth addiction concerns.
FDA Commissioner Marty Makary has resigned from his role effective Tuesday, ending a tenure marked by significant friction with the Trump administration. The departure follows a direct conflict regarding the approval of fruit-flavoured e-cigarettes, a move Makary opposed on the grounds that such flavours could encourage youth addiction. Despite his public health reservations, the White House proceeded to authorise the products, overriding the commissioner's objections.
The specific catalyst for the resignation appears to be the administration's decision to allow flavours including menthol, mango, and blueberry from the Los Angeles manufacturer Glas. Makary had resisted these sign-offs, arguing they conflicted with efforts to combat youth vaping. This stance put him at odds with the administration's broader "save vaping" agenda and the interests of the tobacco industry. Reports indicate that President Trump personally intervened, calling Makary to express dissatisfaction with the pace of the authorisation process.
In a move that contrasts sharply with the internal pressure to remove Makary, President Trump publicly endorsed the resignation on social media. He described the former commissioner as having "done a great job" and a "hard worker" who would have an outstanding career in medicine. Trump confirmed the departure via a posted image of a text message from Makary stating, "Please accept my resignation, effective today." Consequently, Kyle Diamantas, the top food regulator at the agency, has been appointed as acting commissioner pending a permanent appointment.
Makary's time at the helm was complicated by disputes extending beyond vaping policy. He faced accusations from anti-abortion activists of slow-walking safety reviews for mifepristone, a pill used for abortion and miscarriage treatment. Additionally, public health experts criticised his alignment with Health Secretary Robert F. Kennedy's anti-vaccine agenda, noting that changes to vaccine reviews under his watch drew significant scrutiny.
Administration insiders suggest that Health Secretary Robert F. Kennedy was the primary driver behind the plan to oust Makary, though the President ultimately agreed to the move. The decision reflects a prioritisation of industry interests and specific political promises over the commissioner's public health concerns. This dynamic created an environment where Makary reportedly angered lobbyists from the biotech, tobacco, and pharmaceutical sectors, leading to a situation where he had offended almost everyone involved in FDA issues.
The resignation underscores the intense pressure regulators face when balancing scientific caution with political mandates. While the administration framed the removal as a resolution to management struggles, the core issue remains the clash between the FDA's traditional role in protecting public health and the White House's drive to expand market access for flavoured vaping products.
